These mechanisms play a role in the depletion of auto-reactive lymphocytes and immune system renewal. Several molecular and cellular mechanisms are known to be involved in the resetting of the immune system following the AHSCT infusion in MS patients. Different clinical trials revealed that AHSCT with a low density conditioning regimen could be suggested as a suitable candidate approach in the management of MS. Furthermore, this treatment approach was more effective in relapsing remitting MS (RRMS) patients than progressive MS (PMS). The individuals aged < 40 years with a short duration of MS disease have been demonstrated to show a better response to AHSCT administration. Several factors are known to be influenced on the successful rate of AHSCT in patients with MS.
The results obtained from different studies indicate that AHSCT increases the life quality of MS patients. Reihane Mohammadi, 1 Alisam Aryan, 2 Mir Davood Omrani, 1 Sayyed Mohammad Hossein Ghaderian, 1 Zahra Fazeli 1ġDepartment of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran 2Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iranĭepartment of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranĪbstract: Autologous hematopoietic stem cell transplantation (AHSCT) is considered as the novel approach to improve multiple sclerosis (MS) patients with disease-modifying therapies (DMTs)-resistance.